Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Sep 20:12:872.
doi: 10.3332/ecancer.2018.872. eCollection 2018.

Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation

Kai Sun  1 , Cesar Gentille Sanchez  1 , Sai Ravi Pingali  2 , Swaminathan Iyer  2
Affiliations
Case Reports

Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation

Kai Sun et al. Ecancermedicalscience. .

Abstract

Hepatosplenic γδ T-cell lymphoma (HSTCL) is a rare aggressive peripheral T-cell lymphoma. Prognosis is usually poor with a median survival between 8 and 16 months after traditional chemotherapy. Stem cell transplantation (SCT) is promising and with a more intense induction regimen, has yielded positive results. We report the use of pegylated-asparaginase (PEG-asparaginase) along with a conventional anthracycline-containing regimen in a 51-year-old male who was diagnosed with HSTCL, achieved a complete remission, and subsequently underwent peripheral blood SCT and remained in remission at the time of this case report.

Keywords: Hepatosplenic γδ T-cell lymphoma; pegylated-asparaginase; stem cell transplant.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Vose J, Armitage J, Weisenburger D, et al. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. doi: 10.1200/JCO.2008.16.4558. - DOI - PubMed
    1. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia. 2000;14(6):991–997. doi: 10.1038/sj.leu.2401784. - DOI - PubMed
    1. Yabe M, Medeiros LJ, Wang SA, et al. Clinicopathologic, immunophenotypic, cytogenetic, and molecular features of gammadelta T-cell large granular lymphocytic leukemia: an analysis of 14 patients suggests biologic differences with alphabeta T-cell large granular lymphocytic leukemia. Am J Clin Pathol. 2015;144(4):607–619. doi: 10.1309/AJCPJSA1E1YWSZEY. - DOI - PubMed
    1. Belhadj K, Reyes F, Farcet JP, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood. 2003;102(13):4261–4269. doi: 10.1182/blood-2003-05-1675. - DOI - PubMed
    1. Farcet JP, Gaulard P, Marolleau JP, et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood. 1990;75(11):2213–2219. - PubMed

Publication types

LinkOut - more resources